Medicare Law Causes Roche To Hesitate On Oncology Price Increases
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche and Genentech were "circumspect" about implementing price increases given the confusion over Medicare reimbursement, Roche Worldwide Pharmaceuticals Head Burns says. European prices for the companies' oncology products drop.